Skip to main content Accessibility help
×
Hostname: page-component-7479d7b7d-c9gpj Total loading time: 0 Render date: 2024-07-12T21:49:51.391Z Has data issue: false hasContentIssue false

17 - Bevacizumab

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Avastin

Generic?

• No

Class

• Antineoplastic agent

Commonly Prescribed for

(FDA approved in bold)

Monotherapy for glioblastoma following prior therapy

Metastatic colorectal cancer

Metastatic renal cell carcinoma

Metastatic breast cancer

Non-squamous non-small cell lung cancer

• Schwannomatosis

• Ovarian cancer

• Age-related macular degeneration

How the Drug Works

• A recombinant humanized monoclonal immunoglobulin (IgG1) that binds to vascular endothelial growth factor (VEGF) and prevents the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells. It downregulates angiogenesis, improves vascular normalization, and enhances the efficacy of both radiotherapy and chemotherapy

How Long Until It Works

• Days to weeks. May rapidly reduce peritumoral edema, but the actual tumor shrinking effect may take months

If It Works

• Continue every 2 weeks

If It Doesn't Work

• Usually used for symptomatic glioblastomas in an advanced stage but other salvage therapies can be considered depending on the clinical situation

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Generally given to ill and symptomatic patients. Usually given along with dexamethasone, but bevacizumab may allow tapering of corticosteroids

• May be given along with temozolomide, although this is not standard practice

• Coadministration with irinotecan may increase survival

Tests

• Monitor blood pressure (may increase) during treatment

• Urinalysis for proteinuria

• CBC and hepatic function testing during treatment are required

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Many serious AEs (poor wound healing, severe GI complications) are directly related to inhibition of angiogenesis

Notable AEs

• Epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, exfoliative dermatitis

• Less common: rash, diarrhea, thrombocytopenia, neutropenia

Life-Threatening or Dangerous AEs

• Wound healing delays or dehiscence, CSF leak, necrotizing fasciitis

• Hypertensive crisis

• Arterial or venous thromboembolic events

• Severe hemorrhage including retroperitoneal

• Febrile neutropenia, pancytopenia

• Congestive heart failure (rare)

• Hepatotoxicity (rare)

• Ovarian failure

• Gallbladder perforation

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 62 - 65
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Bevacizumab
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.018
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Bevacizumab
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.018
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Bevacizumab
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.018
Available formats
×